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ABSTRACT Since the discovery of penicillin, microbes have been a source of antibi-
otics that inhibit the growth of pathogens. However, with the evolution of multidrug-
resistant (MDR) strains, it remains unclear if there is an abundant or limited supply of
natural products to be discovered that are effective against MDR isolates. To identify
strains that are antagonistic to pathogens, we examined a set of 471 globally de-
rived environmental Pseudomonas strains (env-Ps) for activity against a panel of 65
pathogens including Achromobacter spp., Burkholderia spp., Pseudomonas aeruginosa,
and Stenotrophomonas spp. isolated from the lungs of cystic fibrosis (CF) patients.
From more than 30,000 competitive interactions, 1,530 individual inhibitory events
were observed. While strains from water habitats were not proportionate in antago-
nistic activity, MDR CF-derived pathogens (CF-Ps) were less susceptible to inhibition
by env-Ps, suggesting that fewer natural products are effective against MDR strains.
These results advocate for a directed strategy to identify unique drugs. To facilitate
discovery of antibiotics against the most resistant pathogens, we developed a work-
flow in which phylogenetic and antagonistic data were merged to identify strains
that inhibit MDR CF-Ps and subjected those env-Ps to transposon mutagenesis. Six
different biosynthetic gene clusters (BGCs) were identified from four strains whose
products inhibited pathogens including carbapenem-resistant P. aeruginosa. BGCs
were rare in databases, suggesting the production of novel antibiotics. This strategy
can be utilized to facilitate the discovery of needed antibiotics that are potentially
active against the most drug-resistant pathogens.
IMPORTANCE Carbapenem-resistant P. aeruginosa is difficult to treat and has been
deemed by the World Health Organization as a priority one pathogen for which an-
tibiotics are most urgently needed. Although metagenomics and bioinformatic stud-
ies suggest that natural bacteria remain a source of novel compounds, the identifi-
cation of genes and their products specific to activity against MDR pathogens remains
problematic. Here, we examine water-derived pseudomonads and identify gene clusters
whose compounds inhibit CF-derived MDR pathogens, including carbapenem-resistant P.
aeruginosa.
KEYWORDS Pseudomonas, antagonistic, antibiotic, biosynthetic gene cluster,
multidrug resistance, transposon mutagenesis
The World Health Organization has identified 12 pathogens for which novel antibi-otics are most urgently needed, and carbapenem-resistant Pseudomonas aerugi-
nosa is considered a priority one threat (1). With 10 million deaths predicted annually
by 2050 from multidrug-resistant (MDR) infections (2), the discovery of novel thera-
peutics effective against pathogens is needed. Biosynthetic gene clusters (BGCs) en-
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code bacterial secondary metabolites whose function extends beyond the normal
growth and metabolism of a cell by facilitating a variety of processes, including
antibiotic production. Recent genomic studies suggest that environmental bacteria
represent a continued source of novel BGCs that encode unique products (3–6). In
particular, marine and freshwater-derived bacteria have been the most promising
source of unique products. For example, the novel antibiotic nucleoside analogue 201A
from the deep-sea marine actinomycete Marinactinospora thermotolerans SCSIO was
recently discovered to inhibit MDR Staphylococcus aureus (7). Cocultures of marine
invertebrates and associated bacteria led to the discovery of multiple antagonistic
factors, including keyicin, an anthracycline that inhibits Gram-positive pathogens (8), in
addition to -carbolines and indolactam alkaloids that possess potent antimalarial
activity (9). A natural product from the marine bacterium Pseudoalteromonas was able
to inhibit a multidrug efflux pump, thus increasing the effects of antibiotics against
MDR pathogens (10). Last, lake-derived pseudomonads were active at inhibiting Pseu-
domonas aeruginosa (11), as well as oomycete plant pathogens (12). Although the
prediction of BGCs from metagenomics data and the discovery of new compounds
suggest a continued source for antibiotic discovery, the abundance of novel com-
pounds effective against MDR pathogens remains unknown.
Cystic fibrosis (CF) is an autosomal recessive genetic disease resulting from muta-
tions in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (13).
Mutations within CFTR result in decreased chloride permeability within mucosal mem-
brane tissue (14), leading to increased mucoid production in the respiratory track and
ideal conditions for bacterial colonization and growth (15). CF patients are therefore
susceptible to chronic pulmonary infections and are regularly colonized by species of
Achromobacter (16), Stenotrophomonas (16), Burkholderia (17), and P. aeruginosa (18), all
of which are known to have evolved drug resistance and present complications in the
CF lung. Previously, we showed that CF-derived P. aeruginosa strains (CF-PAs) are
susceptible to environmental Pseudomonas strains (env-Ps) which may also be a source
of natural products that inhibit other pathogens, including MDR strains (11). env-Ps
represent a large, genetically diverse group of bacteria (19, 20) that are ubiquitous in
the environment and are readily isolated from soil (21, 22) and freshwater (23, 24)
habitats. Moreover, env-Ps are known to produce a variety of secondary metabolites
that are involved in functions ranging from plant health and disease to bioremediation
and microbial inhibition (20). Because of the wide range in structure and function of
these metabolites and our earlier findings that water-derived bacteria actively inhibit
pathogens (11), we predicted that env-Ps from distinct water habitats would inhibit
CF-derived pathogens (CF-Ps), including Achromobacter spp., Burkholderia spp., P.
aeruginosa, and Stenotrophomonas spp.
To assay for antagonistic activity against pathogens, we investigated direct interac-
tions between env-Ps and CF-Ps. A collection of pseudomonads was sampled across
time and space, including strains from water systems in the United States, Hungary, and
Germany. Using 471 env-Ps, we performed a population-level analysis in which these
strains were genetically characterized using the gyrB gene and then tested for their
ability to inhibit CF-Ps in one-on-one competitions. We identified several env-Ps with
the ability to inhibit multiple CF-Ps. However, the ability to inhibit MDR CF-PAs was
limited, suggesting that there are fewer novel natural products available for discovery
against the most resistant pathogens. To target diverse loci whose products were active
against the most devastating pathogens, env-P inhibition and phylogenetics were
merged to identify genetically distinct antagonistic strains. Transposon (Tn) mutagen-
esis and genome sequencing were utilized on four env-Ps that inhibited multiple CF-Ps.
Using this approach, we identified six dissimilar biosynthetic gene clusters (BGCs)
whose products were able to inhibit MDR pathogens, including carbapenem-resistant
P. aeruginosa. Computational analyses revealed that these BGCs differ from each other
and were infrequent in the Joint Genome Institute (JGI) and NCBI databases, suggesting
these strains may encode novel antagonistic factors. Although our results imply that
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fewer novel antibiotics are available for discovery against MDR pathogens, we offer a
strategy to identify BGCs whose products are potentially active against pathogens.
RESULTS
Population-level diversity of environmental pseudomonads. Strains were iso-
lated from different water habitats to obtain a diverse group of env-Ps. Totals of 163,
160, and 148 strains were obtained from watercolumns in the United States, Germany,
and Hungary, respectively, resulting in a collection of 471 pseudomonads. In the United
States, Lake Erie has a surface area of 25,667 km2 and a mean depth of 19 m that
borders Canada and has been impacted by human activity. During the time of sam-
pling, the water temperature was 11.5°C, and the lake was not ice covered (25). Strains
from Hungary were obtained from Lake Balaton, which is in the Transdanubian region
and is the largest lake in central Europe; it has a surface area of 596 km2 and a mean
depth of 3.2 m. During sampling, the lake was covered by thin ice (2 to 5 cm) with
negligible snow cover, and the water temperature was 3.5°C (26). env-Ps from Germany
were obtained from the Darss-Zingst estuary in the state of Mecklenburg-West Pom-
erania, which represents a brackish habitat and had a temperature of 4.0°C. The
ecological factors within these habitats likely differ and may select for strains producing
diverse metabolites within and between environments. As an initial examination of
strain identity, the gyrB gene was amplified, sequenced, and BLAST searches were
performed against the NCBI nucleotide database. All strains were identified as Pseu-
domonas at the genus level. A neighbor-joining phylogenetic tree was created from
each of the 471 gyrB housekeeping gene sequences to visualize the population-level
genetic diversity (Fig. 1). Eleven populations, each consisting of 18 or more strains, were
identified based on nucleotide divergence and branching patterns. To investigate the
ecological distribution of natural env-Ps by population, data corresponding to derived
habitats were superimposed onto the phylogeny (Fig. 1, inner bars). All populations
were observed to consist of isolates from at least two different habitats. Although few
populations were composed of strains from one location, populations 3 and 5 con-
tained strains mostly from the United States, and populations 11 and 6 were mostly
from Germany and Hungary, respectively. Populations 4, 6, 9, and 10 consisted mostly
of German and Hungarian samples, while populations 1, 2, 7, and 8 were mixed,
suggesting that strains isolated from different habitats were closely related. While most
strains differed at the gyrB locus, all populations had at least two strains with identical
sequences, suggesting the presence of similar or clonal isolates. These results show the
population-level genetic diversity among env-Ps and that the groups were composed
of related strains from different water habitats.
Environmental pseudomonads inhibit CF-derived pathogens. With the evolu-
tion of pathogens that resist antibiotics, it is essential that new therapeutics are
discovered to treat bacterial infections. We previously demonstrated that competitive
interactions occur among pseudomonads and CF-PAs (11). Here, we sought to deter-
mine if environmental strains from water habitats were active in their ability to inhibit
a panel of diverse CF-Ps. To assess competition, we utilized a plate-based assay in which
strains were cocultivated in one-on-one competition and screened for antagonistic
activity by a zone of clearing of at least 1 mm (Fig. 2, inset). We competed all 471
environmental isolates against a panel of 65 pathogens to determine if natural isolates
could inhibit different CF-derived clinical strains. The collection consisted of nine
Achromobacter, 20 Burkholderia, 33 P. aeruginosa, and three Stenotrophomonas strains.
These pathogens are known to colonize the CF lung and are responsible for many of
the bacterial infections caused in these patients (21, 27, 28). From all antagonistic
assays, 1,530 inhibitory events were observed (see Table S1 in the supplemental
material) that consisted of 579 events from the United States, 359 events from
Germany, and 592 events from Hungary that directly inhibited the growth of nine
Achromobacter, 19 Burkholderia, 31 P. aeruginosa, and three Stenotrophomonas strains
(Fig. 2). Only one Burkholderia strain and one P. aeruginosa strain were not inhibited by
any env-P. A chi-square test was used to determine whether the number of antagonistic
Identification of Active Compounds against Pathogens Applied and Environmental Microbiology













































events by env-Ps differed by location with respect to each of the four pathogen genera.
The number of events was not proportional to strain isolation by location for Achro-
mobacter (2  112.29, df  2, P  0.0001), Burkholderia (2  120.37, df  2,
P  0.0001), Pseudomonas (2  12.69, df  2, P  0.0017), or Stenotrophomonas (2 
FIG 1 Phylogenetic analysis and antagonistic activity among env-Ps. Population structure for 471 environmental pseudomonads by neighbor-joining analysis
of the gyrB sequence, merged with data for habitat (inner bars: purple, United States; dark blue, Germany; light blue, Hungary) and antagonistic activity (outer
bars; black and red) against 65 CF-Ps. The magnitude of antagonism is indicated by bar height. Strains that inhibit more than nine pathogens are indicated
by black bars. Populations are shaded and numbered 1 to 11. Tn mutagenesis was used to identify BGCs involved in antagonistic activity in strains 06C126,
09C129, LG1D9, and LH1G9 (indicated by the green arrows).
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23.61, df  2, P  0.0001). In general, env-Ps from the United States performed as well
as or better than strains from the other two locations against CF-Ps, but strains from
Germany and Hungary performed relatively poorly against Achromobacter and
Stenotrophomonas pathogens. env-Ps from all locations performed similarly against
CF-PAs.
We next determined if any of the env-Ps inhibited MDR CF-PAs. Using the Kirby-
Bauer disk assay, we identified 11 of 33 CF-PAs that exhibited an MDR phenotype,
defined as resisting the effects of four or more antibiotics (Table 1). In total, 104
antagonistic events were observed among 10 MDR CF-PAs (Fig. 2, numbers 4 to 7
above the bars). Of these pathogens, all 10 were antagonized by at least two env-Ps,
and eight were inhibited by 10 or more env-Ps. Moreover, 73 antagonistic events were
observed by 59 env-Ps against MDR CF-PA strains AU11650, AU12176, AU14282,
AU17108, AU17787, AU18005, AU19092, AU28855, and AU29014 (Table S2), which are
resistant to both carbapenems tested; this classified these clinical isolates as priority
one pathogens, as defined by the WHO (1), for which antibiotics are urgently needed.
CF-PA strain AU29014 is resistant to all known antibiotics except colistin and was only
inhibited by six env-Ps. Since less env-P activity seemed to be observed against MDR
CF-PAs (Fig. 2), a linear regression was performed to determine if the susceptibility of
MDR pathogens was negatively related to the magnitude to which pathogens are
resistant to antibiotics. The analysis showed that the number of antagonistic events
dropped by nearly two with every unit increase in the number of antibiotics which a
pathogen resists. Thus, the more-drug-resistant CF-PAs were the least antagonized by
env-Ps. A similar trend was observed among CF-Ps and antagonistic activity observed
from the env-Ps (Fig. 2); however, antibiotic susceptibility and resistance standards are
not documented by the Clinical and Laboratory Standards Institute (22) for Achromo-
bacter, Burkholderia, and Stenotrophomonas spp., so strains of these genera were not
FIG 2 Antagonistic events of env-Ps against CF-Ps. A competition plate assay was used to determine antagonistic activity (inset). A
total of 471 env-Ps were competed against 65 CF-Ps that resulted in 30,615 individual competitions. Of the 1,530 antagonistic events
observed, activity originated from 579 U.S. (purple bars), 359 German (dark-blue bars), and 592 Hungarian (light-blue bars) env-Ps that
inhibited the growth of nine Achromobacter, 19 Burkholderia, 31 P. aeruginosa, and three Stenotrophomonas strains. Black arrows
indicate activity by three antagonistic strains. Only one Burkholderia strain and one P. aeruginosa strain were not inhibited by any
env-P. P. aeruginosa strains were tested for susceptibility against eight antibiotics using the Kirby-Bauer disk assay. Numbers above
the antagonistic bar data represent the number of drugs a particular pathogen resists, indicated in Table 1. Linear regression analysis
showed that the number of antagonistic events to a pathogen was inversely related to antibiotic resistance.
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tested for an MDR phenotype. The results indicated that env-Ps engage in competitive
interactions against CF-Ps, but significantly fewer antagonistic events were observed
against MDR CF-PAs, suggesting that fewer natural drugs are available for discovery
that are effective against the most-antibiotic-resistant pathogens.
Strategy to identify distinct env-P BGCs that inhibit pathogens. Two environ-
mental isolates from different populations, habitats, and with dissimilar antagonistic
profiles were selected for Tn mutagenesis, the purpose being that these env-Ps likely
produce distinct compounds, encoded by different BGCs, that inhibit CF-Ps. Strain
02C26 was isolated from the United States, mapped to population 1, and inhibited
seven CF-Ps (Table S3); strain LH1G9 was from population 4, obtained from a freshwater
lake in Hungary, and inhibited four P. aeruginosa and six Burkholderia strains. Although
Tn insertion results identify a single mutated locus, secreted compounds may be
encoded by multiple genes within a particular chromosomal region. If a BGC was
disrupted by a Tn and the mutant exhibits a loss-of-inhibition (LOI) phenotype, that
region was likely involved in antibiotic production and secretion. The wild-type strains
were sequenced and annotated, and all had multiple predicted BGCs (Table S4).
With both 02C26 and LH1G9 env-Ps, Tn insertions were found within BGCs (Table 2).
For strain 02C26, eight independent LOI mutants were identified (Table 3). Three Tn
insertions disrupted genes in a 53-kb BGC (JGI identifier [ID] 161819466 and Fig. 3A)
that contained 41 predicted open reading frames (ORFs) (Table S5). ORFs 23 and 24
were disrupted and predicted to encode a nonribosomal peptide synthetase (NRPS)
(Fig. 4A) and a hypothetical protein (Table 3), respectively. The other mutation occurred
TABLE 1 Antibiotic resistance of CF-PA strains
CF-PA strain
Antibiotic (concn [g/disk]) resistance resulta
CL 10 CB 100 C 30 MEM 10 IPM 10 NN 10 CIP 5 CAZ 30
AU8215 S S R I R S S S
AU8660 S R R S S S S S
AU9276 S S S S S S S S
AU10014 S R I S S S S R
AU11650b S R R R R S R R
AU12175 S S R S S S R S
AU12176b S R I R R S I R
AU14282b S S R R R S R S
AU15031 S S R S S R I S
AU15152 S S R S S S S S
AU15873 S S R S S S S S
AU16000b S R R S R S R S
AU16821 S I I S S R R S
AU17108b S I R R R S R I
AU17152 S S R S S S R S
AU17766 S S R S I R I S
AU17787b S R R R R S R R
AU18005b S R S R R R R R
AU18081 S S R S R I I S
AU18234 S S R S S S S S
AU18422 S S S S S S S R
AU19092b S R R R R S S I
AU19324 S R I S S R S S
AU19425 S S R S S S I S
AU20339b S S R I R R R S
AU23316 S I R S S R S R
AU26901 I S I S S R I S
AU27145 S S S I R S S S
AU27282 S S I S S I S S
AU28855b S R R R R R I S
AU29014b S R R R R R R R
AU29142 S S I S S S I S
AU30307 S S S S S S R S
aCL, colistin; CB, carbenicillin; C, chloramphenicol; MEM, meropenem; IPM, imipenem; NN, tobramycin; CIP,
ciprofloxacin; CAZ, ceftazidime; S, susceptible; I, intermediate; R, resistant.
bMDR strains.
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in ORF 26; ORFs 26 and 27 encode putative products of a macrolide antibiotic efflux
system. The other five Tn insertions disrupted loci in a 79-kb gene cluster (JGI ID
161819467 [Table 2]) that contained 53 putative ORFs and was predicted to encode a
bacteriocin-like compound (Fig. 3B and Table S6). Three Tn insertions were within ORF
20 (Table 3), which was predicted to encode an NRPS (Fig. 4B). The other two insertions
occurred in ORFs 23 and 32, which were predicted to encode another NRPS and a
zinc-dependent dipeptidase (Table 3), respectively. From all mutants, three NRPSs were
identified within two BGCs (Fig. 4A and B) and likely contribute to the production of a
nonribosomal peptide. In addition to these Tn-disrupted regions, other ORFs potentially
encoding iron uptake systems were located within the BGC, suggesting that this locus
may be associated with a siderophore (Table S6; ORFs 26, 42, and 47). Of the seven
BGCs predicted in LH1G9, one mutant was identified that resulted in the LOI pheno-
type. The Tn insertion disrupted a BGC that was 64 kb (JGI ID 161848994 and Fig. 3C)
and consisted of 30 ORFs (Table S7). ORF 14 was mutated (Table 3) and predicted to
encode an NRPS (Fig. 4C). Based on the BGC size and gene content of the env-Ps 02C26
and LH1G9 (Fig. 3A to C), it is apparent that these loci are diverse in structure and likely
encode distinct products that contribute to antagonistic activity.
Identification of BGCs whose products are potentially active against MDR
CF-Ps. We utilized the above-mentioned strategy to identify BGCs whose products
inhibit multidrug- and carbapenem-resistant pathogens. Strain 09C129 was isolated
from the United States, mapped to population 2 (Fig. 1), and inhibited 10 CF-Ps (Table
S3), of which AU12176 and AU17108 were MDR CF-PAs (Table 1). Strain LG1D9 was
isolated from brackish water in Germany, mapped to population 11, and antagonized
20 CF-Ps, including the growth of CF-PAs AU12176, AU17108, and AU20339 (Table S3);
strains AU12176 and AU17108 were resistant to four and five antibiotics, respectively,
including both carbapenems, while AU20339 was resistant to four antibiotics, including
TABLE 2 Tn-mutated BGCs among env-Ps 02C26, 09C129, LG1D9, and LH1G9
Strain BGC size (kb) Putative BGC product/function BGC coordinates JGI BGC ID no. No. of Tn mutants
02C26 53 Pyoverdine/NRPS 1639452–1692405 161819466 3
79 Pyoverdine/bacteriocin/NRPS 1906137–1985107 161819467 5
09C129 23 Phenazine 6197676–6220462 161816930 5
50 NRPS 3874653–3924442 161816936 3
LG1D9a 6 Fatty acid metabolism 3420434–3426705 5
LH1G9 65 NRPS 2547071–2611595 161848994 1
aThe Tn was not inserted into a BGC predicted by JGI IMG or antiSMASH.
TABLE 3 env-P-mutated genes involved in antagonistic activity
Strain JGI BGC no. ORF no. No. of Tn inserts Predicted function JGI locus tag
02C26 161819466 23 1 NRPS Ga0151585 111533
161819466 24 1 Hypothetical Ga0151585 111534
161819466 26 1 Efflux pump Ga0151585 111536
161819467 20 3 NRPS Ga0151585 111764
161819467 23 1 NRPS Ga0151585 111767
161819467 32 1 Zinc-dependent dipeptidase Ga0151585 111776
LH1G9 161848994 14 1 NRPS Ga0199208 112386
09C129 161816930 16 1 Phenazine biosynthesis Ga0139558 115541
161816930 20 4 Phenazine biosynthesis Ga0139558 115545
161816936 11 1 NRPS Ga0139558 113529
161816936 16 1 NRPS Ga0139558 113534
161816936 20 1 NRPS Ga0139558 113538
LG1D9 6 1 Flavin adenine dinucleotide binding protein Ga0172616 112987
8 1 Peroxiredoxin Ga0172616 112989
10 2 Fatty acid hydrolase Ga0172616 112991
Identification of Active Compounds against Pathogens Applied and Environmental Microbiology













































imipenem, with an intermediate phenotype to meropenem (Table 1). Strain LG1D9 also
inhibited 11 other P. aeruginosa strains and seven Burkholderia strains. Utilizing the
phylogenetic, habitat, and antagonistic data, env-P 09C129 and LG1D9 data were
unique compared to each other and to 02C26 and LH1G9, suggesting that the BGCs
would be distinct.
For strain 09C129, two BGCs were identified from eight independent Tn insertions
(Table 2). Five Tn insertions were found in a BGC that was 23 kb (Fig. 3D; JGI ID
161816930) and was predicted to encode a phenazine. Within this cluster (Table S8),
ORFs 16 and 20 had one and four Tn insertions and encode a putative phenazine
biosynthesis protein A/B and a phenazine biosynthesis protein PhzE, respectively (Table
3). Phenazines are nitrogen-containing heterocyclic compounds that are known to have
broad-spectrum antibiotic properties and involvement in virulence (23). Additionally,
multiple genes were predicted to encode a secretion system. The other insertions
occurred in three different loci in a 50-kb BGC (Fig. 3E; JGI ID 161816936) that has 32
predicted ORFs (Table S9). One mutant had the Tn insertion within ORF 11 (Table 3),
which was predicted to encode a condensation domain-containing protein (Fig. 4D).
The other mutants had Tn insertions in ORFs 16 and 20 (Table 3), which were predicted
to encode amino acid adenylation and condensation domain proteins (Fig. 4D), respec-
tively, all of which are characteristic domains of an NRPS. These results suggest that
these two BGCs play an important role in producing a nonribosomal peptide that
actively inhibits MDR CF-PAs. For strain LG1D9, four LOI mutants were identified, and
the Tn insertions were found within a 6.2-kb region (Table S10), disrupting three
potential genes (Fig. 3F). ORF 6 was predicted to encode a flavin adenine dinucleotide
(FAD) binding protein, ORF 8 was predicted to encode a peroxiredoxin, and two Tn
insertions were identified in ORF 10, which was predicted to encode a fatty acid
hydrolase (Table 3). This locus was not a predicted BGC by JGI GOLD (24), antiSMASH
(29), or PRISM (30).
FIG 3 Tn insertions were identified in strains 06C126, LH1G9, 09C129, and LG1D9. (A to C) Tn-mutated BGCs with JGI ID numbers 161819466 (A) and 161819467
(B) were identified in strain 02C26, and BGC 161848994 (C) was identified in LH1G9. All three loci were predicted to encode a nonribosomal peptide. (D and
E) In 09C129, BGCs 161816930 (D) and 161816936 (E) were identified and predicted to encode a phenazine and nonribosomal peptide, respectively. (F) With
strain LG1D9, four Tn insertions were identified in genes that were not predicted to be a BGC. ORFs are represented by solid-color filled arrows; different colors
represent dissimilar proteins (listed in Tables S4 to S9). Right and left pointed arrows signify loci on forward and reverse DNA strands, respectively. Red lines
indicate the position of the Tn insertion. Predicted compound structures follow each BGC and were determined using PRISM.
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Frequency of identified BGCs among sequenced genomes. Two databases were
utilized to determine if the discovered BGCs were unique among sequenced genomes.
First, BLAST searches of each BGC were performed against the NCBI nucleotide Micro-
bial Genomes database to search for other similar gene clusters. Although similar BGCs
were identified in NCBI, none were 100% identical to other gene clusters or frequent in
the database (Table S11). For strain 02C26, the 53-kb gene cluster (JGI ID 161819466)
had a query cover of 95% and 82% nucleotide identity to a locus in Pseudomonas putida
KT2440 (31); the next closest hit was Pseudomonas monteilii strain USDA-ARS-USMARC-
56711, which showed query coverages of 59% and 80% nucleotide identity. The other
BGC in strain 02C26 (JGI ID 161819467) was most similar to Pseudomonas plecoglossi-
cida strain XSDHY-P, with query coverages of 28% and 85% nucleotide identity.
Interestingly, the closest hits of each BGCs were identified in different Pseudomonas
species. For strain 09C129, which was able to inhibit MDR CF-PAs, both BGCs were
identified among Pseudomonas chlororaphis strains. One BGC (JGI ID 161816930)
was almost identical to a gene cluster in strain DSM 50083; the other BGC (JGI ID
161816936) had a coverage of 69%, suggesting that the loci were different in content.
We identified one BGC in the other two strains, LG1D9 and LH1G9, and each of those
clusters was closely related to loci in only two other strains from the species Pseu-
domonas fluorescens and Pseudomonas veronii, respectively. Thus, the BGCs were rare in
the NCBI Microbial Genomes database.
Because nucleotide divergence within a BGC may be greater than the amino acid
similarity, env-P BGCs were also analyzed using the JGI Atlas of Biosynthetic Gene
Clusters (ABC) and grouped based on Pfam (32). To date, the JGI database has nearly
100,000 sequenced bacterial genomes and over 1.1 million predicted BGCs. To visualize
FIG 4 Predicted domains of NRPSs in env-Ps. (A and B) Strain 02C26 has two BGCs which were each
predicted to encode NRPSs, as follows: ORF 23 was identified in BGC with JGI ID 161819466 (A) and ORFs
20, 22, and 23 were identified in BGC 161819467 (B). (C) Strain LH1G9 has two loci that encode an NRPS
which were identified in ORFs 14 and 15 of BGC 161848994. (D) In strain 09C129, ORF 16 was found in
BGC 161816936 and was predicted to encode an NRPS with associated ORFs 11 to 13 and 18 to 20. NRPS
domains are shown as individual circles with predicted functions involved in condensation (C; in pink),
adenylation (OHBu, 3-hydroxybutanoic acid; Dab, 2,4-diamino-butyric acid; and OHOm, N5-hydroxy-L-
ornithine; in red), thiolation (T; in gray), epimerization (E; in dark red), and thioesterase (TE; in black).
Other domains identified were antibiotic resistance (AMR235, MacB subunit of efflux pump; AMR262,
MatE: efflux protein; and AMR116, puromycin major facilitator superfamily [MFS] transporter; in maroon),
and dehydratase (DH; blue). Numbered ORFs correspond to Tables S4, S5, S6, and S8.
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BGC diversity, a heat map was generated using the top 19 BGCs identified in the
JGI-ABC from 02C26, 09C129, and LH1G9, giving hits to the most related 95 loci based
on Pfam content (Fig. 5). The results showed that each BGC was diverse and grouped
into clades C1 to C5, suggesting dissimilar protein content (Fig. S1). The BGC from
LH1G9 grouped with 16 other strains in C1, and 10 of those were identical. Although
they are the same based on Pfam content, these 11 BGCs represent less than 0.0009%
of all loci in the database, suggesting that the clusters were rare. The BGCs in strain
FIG 5 Heat map of similar Pfam protein families in the JGI ABC to 02C26, LH1G9, 09C129, and LG1D9 BGCs. The 95 most similar BGCs were identified and used
to show similarities and differences within each cluster. Five clades were generated in the analysis, C1 to C5. The JGI ABC Pfam designations are listed on the
top x axis and correspond to Table S11. The heat map color shading represents the number of each Pfam protein family in a BGC. Unique, single, and multiple
protein families in a BGC range from 0 to 5, with yellow representing 0 protein families and lightest green to darkest green representing 1 to 5 protein families.
The left y axis consists of BGC phylogeny determined by number and content of similar protein families. Tree branch lengths were determined using the Jaccard
index scores of all protein families. The right y axis lists strains, with 02C26, LH1G9, and 09C129 in red; their BGC is boxed with a black dashed line.
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02C26, JGI IDs 161819466 and 161819467, grouped within C3 and C2, respectively.
Clade C2 consists of 21 strains, and no loci exactly matched the BGC; C3 consists of 20
strains, and only Pseudomonas sp. strain S3E7 has an identical BGC. Strain 09C129 has
BGCs JGI IDs 161816930 and 161816936 that grouped within C4 and C5. C4 consisted
of 17 strains, including BGC 161816930, which were identical. As with LH1G9, these
identical loci represent only a small percentage of the BGCs in the database. Clade C5
consists of 26 strains, and no BGC was identical to BGC JGI ID 161816936. Most strains
within all groupings consisted of pseudomonads. LG1D9 was not used in this analysis
since the Tn-mutated loci were not within a BGC identified by antiSMASH or the
JGI-ABC. Together, these results suggest that the env-P BGCs were distinct from each
other and infrequent among bacteria in the JGI-ABC database.
DISCUSSION
Recent studies suggest that water-derived bacteria encode a collection of undis-
covered natural products that might be devolved to target pathogens (4, 8, 33, 34).
Given that env-Ps thrive in freshwater and have known applications in agriculture,
bioremediation, and health (5, 20), we reasoned that pseudomonads isolated from
different aquatic systems could maintain unique metabolic pathways and produce
compounds that inhibit pathogens. With over 1,500 antagonistic events observed,
water-derived env-Ps represent a source of strains that actively inhibit CF-derived
clinical strains (Fig. 2). Moreover, the antagonistic plate assay used in this study only
tested for activity under one medium type. Changing nutrients may affect the regula-
tion of other metabolites involved in activity. Thus, the results presented here likely
represent a conservative estimate of activity by these strains and possibly the produc-
tion of novel drugs. Even in the current antibiotic crisis, uncertainty remains as to
whether the number of undiscovered drugs that are effective against MDR pathogens
are many or few. Our data show that env-Ps were less active against MDR pathogens,
which implies that fewer drugs may be available for discovery that inhibit MDR
pathogens. Although these results only represent activity from culturable env-Ps, we
propose that this prediction extends to unculturable strains since certain genes,
acquired through lateral transfer, confer resistance against multiple antimicrobial com-
pounds regardless of cultivation. For instance, the NDM-1 gene encodes an enzyme
that confers resistance to most -lactams (35, 36), multidrug efflux pumps recognize
different antibiotics so one pump is effective against different drugs (37–39), and
plasmids carry resistance to “last-resort antibiotics” (40), including carbapenem and
colistin (41), which are readily acquired through conjugation. Because a single mech-
anism can confer resistance against multiple antibiotics, it is unlikely that novel
effective compounds that evade resistance mechanisms are abundant. The reduced
activity against MDR CF-PAs that we observe supports the idea that few natural
products are available for discovery that inhibit the growth of MDR pathogens.
With the increased interest in natural products as a source for combatants that
inhibit pathogens, powerful computational programs, such as antiSMASH (42), Cluster-
Finder (4), and MIBiG (43), were developed and have identified thousands of BGCs from
environmental strains; however, connecting gene clusters to novel antibiotic discovery
is difficult. To facilitate this process, we merged population-level structure (Fig. 1),
antagonistic events (Fig. 2), and Tn mutagenesis to identify different loci whose
products are involved in antagonistic activity (Fig. 3). PRISM was used to identify
putative structures based on gene content, and the results suggested the production
of dissimilar compounds (Fig. 3A to E). The two BGCs identified in strain 02C26 were
genetically distinct and separated by 213.7 kb on the chromosome. The 53-kb BGC (Fig.
3A) was predicted to encode an NRPS (Fig. 4A). Adenylation, condensation, and
thiolation domains are characteristic of these structures and likely contribute to the
production of a nonribosomal peptide. Moreover, NRPSs are diverse in structure and
function and synthesize a wide variety of peptides (4, 44), including most known
antibiotics (45). Other genes within the BGC may be involved in modifying the peptide
or in export of the compound. For instance, ORFs 26 and 27 (Table S5) have putative
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products predictive of macrolide efflux systems. Macrolides are a class of antibiotics,
suggesting that the NRPS may encode a macrolide-like compound and efflux system for
drug production and resistance. This gene cluster was similar to a locus in P. putida
KT2440; although this strain has been well characterized and recently resequenced to
further understand its metabolic capabilities (31, 46), it has not previously been shown
to inhibit pathogens. The other identified BGC in 02C26 was 79 kb (Fig. 3B and Table
S6), consisting of 53 putative ORFs, and was predicted by antiSMASH to encode two
large NRPSs and a small NRPS (Fig. 4B) that showed similarity to components involved
in the synthesis of pyoverdine, a fluorescent siderophore produced by certain pseu-
domonads (47, 48). Some bacteria have been shown to produce sideromycins that are
siderophores with an attached antibiotic (49). These “Trojan horse” molecules inhibit
bacteria that sequester iron from the environment. Although sideromycins have not
been identified in Pseudomonas spp., it is likely that env-Ps express such compounds,
especially since Pseudomonas spp. as a group are known for diverse siderophore
production. To further elucidate the functions of these loci, a gene-by-gene knockout
deletion study may shed light upon the encoded product and demonstrate if one locus
depends on the other for activity but not the reciprocal.
In strain 09C129, two BGCs were also identified and predicted to encode a phena-
zine and NRPS, which were 23 kb (Fig. 3D and Table S8) and 50 kb (Fig. 3E and Table
S9) in size, respectively. Phenazines are characterized by a nitrogen-containing hetero-
cyclic compound and are decorated by different functional groups that contribute to
their structural and metabolic diversity (50). These compounds have a wide range of
activity that contributes to their behavior and ecological fitness (23), and they have
known antibiotic activity among Pseudomonas strains (51–53). In addition to phenazine
biosynthesis genes, the BGC has 10 loci that were predicted to encode a secretion
system. The other BGC was predicted to encode an NRPS (Fig. 4D). ORF 16 encodes the
characteristic adenylation, thiolation, and condensation domains, while ORFs 11 to 13,
19, and 20 were also predicted to contribute to the production of the peptide (Fig. 4D).
This collection of domains, although not within a single NRPS, may reflect recombina-
tion events between different domains with the potential to synthesize a hybrid NRPS,
a phenomenon that has been observed in P. aeruginosa (54). To that end, the most
closely related genes that encode the adenylation and condensation domains are from
Bacillus (Table S9, ORF11) and Pseudomonas (Table S9, ORF16), suggesting that hori-
zontal gene transfer contributed to the evolution of this locus.
In 02C26 and 09C129, both BGCs in each strain were predicted to contribute to the
production of the antagonistic factor since transposon insertions in these loci produced
a LOI phenotype. Coregulation of metabolites from distinct gene clusters has been
identified in other organisms. Pseudomonas protegens Pf-5 produces two antibiotics,
2,4-diacetylphloroglucinol (DAPG) and pyoluteorin, whose BGCs are 3.7 Mb apart (55).
An intermediate of DAPG not only activates the genes which produce pyoluteorin in
strain Pf-5, but it also signals other P. protegens strains to produce pyoluteorin (56). This
type of cooperative regulation among organisms has also been observed among fungi
(57). Penicillium fuscum and Penicillium camemberti/P. clavigerum are extremophiles
that, when cultured together, produce berkeleylactone A, an antibiotic that inhibits
methicillin-resistant Staphylococcus aureus, Streptococcus pyogenes, and Bacillus anthra-
cis. Although the mechanism of regulation is unknown, both species must be present
to produce the drug, which suggests that different gene clusters are involved in
compound synthesis. Only one BGC that contributed to antagonistic activity was
identified between strains LH1G9 (Fig. 3C) and LG1D9 (Fig. 3F). The gene cluster in
LH1G9 was predicted to encode two NRPSs (Fig. 4C). Although only one NRPS was
identified with Tn mutagenesis, both of these loci might be involved in the production
of a single peptide, considering their close proximity in the genome. It is also possible
that other substances, metabolites, and regulators could play a synergic role for the
observed effects that were not identified by the Tn screen. Furthermore, antagonistic
activity by prophage may occur through lysis of the phage itself (58); however, no Tn
inserts that disrupted a prophage were identified in this study.
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A goal of this study was to identify novel BGCs that can be further pursued to
identify and inform the production of new, potentially active antagonistic compounds.
To accomplish this task, BGCs were mined in the NCBI and JGI ABC databases. Both
searches showed that the BGCs were rare in the databases, and the heat map provided
a visual representation of similar gene clusters (Fig. 5). No BGCs, including ones from
the same strains, grouped into the same clade, which reflects the diversity of the loci.
Although only the top 95 BGCs were searched in the JGI ABC, the results suggest that
pseudomonads have clusters that are similar to well-known antibiotic producers
(Fig. 5). For instance, three Streptomyces strains grouped in C5, proving evidence that
the antagonistic Pseudomonas strains encode potentially active products that may
represent an alternative source of effective compounds. The identification of BGC gene
content through Tn mutagenesis (Fig. 3) and its predicted structure (Fig. 4) together
with mining of those loci in databases (Fig. 5), the approach we adopted, can provide
valuable information on the products and assist in the identification of new com-
pounds. In addition, the wild-type and mutant strains can be biochemically coanalyzed
to pinpoint active fractions through techniques such as high-performance liquid chro-
matography with subsequent purification and characterization of the active com-
pounds. This strategy can facilitate the discovery of new compounds with potential for
therapeutic use. env-Ps 09C129 and LG1D9 represent exceptional candidates for this
workflow because both inhibited carbapenem-resistant CF-PAs that are priority one
pathogens for which new antibiotics are currently needed (1). Finally, this drug discov-
ery approach was proven effective in the Tiny Earth and Small World Initiative teaching
curricula (59). Thus, the strategy used here could be implemented worldwide in a
student crowdsourcing effort, in parallel with the Tiny Earth Chemistry Hub, to hasten
the discovery of rare products to be used for the development of antibiotics against
highly resistant pathogens.
MATERIALS AND METHODS
Strain isolation and growth conditions. Water samples were obtained from Lake Erie in the United
States in February 2012, from the shore of the Darss-Zingst estuary in Germany in February 2016, and
from Lake Balaton off the shore of Tihany in Hungary in February 2016. The Lake Erie was sampled during
surveys aboard the Canadian Coast Guard Ship (CCGS) Griffon. U.S. water samples were obtained from
the Central Basin station EC1326 and collected from a depth of 1 m and a temperature of 1.5°C using a
10-liter Niskin bottle on a metered winch. For German and Hungarian samples, surface water was
obtained from shore using a 1-liter Niskin bottle. All water samples were passed over 0.2-m-pore-size
47-mm single-wrapped filters (Pall Corporation) to capture bacteria. Filters were then cultured on
cetrimide agar (Fluka Analytical) at 23°C to select for pseudomonads. To purify strains, colonies were
picked and restreaked two times on sterile nutrient broth (NB) solid medium (BD Difco) with 1.5% agar
(BD Difco). CF-Ps, including P. aeruginosa, and different species of Achromobacter, Burkholderia, and
Stenotrophomonas were gifted by John LiPuma at the University of Michigan. env-Ps and CF-Ps were
grown at 23°C and 37°C, respectively, in NB liquid or agar medium. For transposon (Tn) mutagenesis
(described below), the Pseudomonas strain was grown in NB. The Escherichia coli helper strain HB101 was
grown in lysogeny broth (LB) liquid medium with 150 g/ml ampicillin (Ap), and strain CC118 carrying
pBAM1 was grown in LB with 50 g/ml kanamycin (Km) and 30 g/ml chloramphenicol (Cm), as
previously described (60). E. coli strains were incubated at 37°C.
Gene sequencing and phylogenetic analysis. For gene sequencing, bacterial strains were grown in
liquid culture for 2 days in NB at 23°C with shaking. A 10-l sample was treated with Lyse-N-Go (Thermo
Fisher Scientific, Rockford, IL) to extract and prepare genomic DNA as the template for PCR. Primers
targeting the gyrB gene (gyrB 271 forward primer, 5=-TCB GCR GCV GAR GTS ATC ATG AC-3=; gyrB 1022
reverse primer, 5=-TTG TCY TTG GTC TGS GAG CTG AA-3=) were used to amplify and sequence the locus.
PCR conditions were 92°C denaturation for 10 s, 65°C annealing for 60 s, and elongation at 72°C for 90
s, repeated 29 times. OneTaq DNA polymerase (New England BioLabs) was used for amplification. Sanger
sequencing was performed by the University of Chicago Comprehensive Cancer Center DNA Sequencing
and Genotyping Facility. A nucleotide alignment was generated from 652 bp of the gyrB gene, and a
neighbor-joining tree was constructed using Jukes-Cantor nucleotide distance measurement in CLC Main
Workbench. Bootstrapping was performed in 100 replicates. The iTOL program was used to view the tree
and overlay data corresponding to antagonistic activity (61).
Antagonistic activity. env-Ps were cultured for 20 h in NB medium at 23°C with shaking in a 96-well
plate prior to the assay. To generate a bacterial lawn of the pathogen, 50 l of a single culture was spread
on NB agar plates. Subsequently, 1 l of each environmental strain was transferred to the lawn using a
96-pin replicator (Boekel microplate replicator). Strains were cocultured at 23°C for 20 h to allow growth
of the environmental strains. Assays were then temperature shifted to 37°C to provide for optimal growth
of the pathogen. Antagonistic activity was scored as positive for a given Env-P if a zone of clearing of at
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least 1 mm was produced in the pathogen lawn surrounding the env-P strain. To confirm positive results,
all inhibitory strains were selected and replicated at least three times against all pathogens. A chi-square
test was used to determine whether the number of events differed by location with respect to each of
the four pathogen genera. The expected proportions of the total observed events were 0.34, 0.31, and
0.35 for strains from Germany, Hungary, and the United States, respectively, because isolated strains from
these countries represented 34%, 31%, and 35% of the 471 tested strains, respectively, each of which was
tested against all pathogens in each genus. Linear regression was used to determine whether the
number of observed events was related to the known antibiotic resistance of Pseudomonas pathogens.
The model included the number of strains derived from each location for which an event was observed
as the response variable, with the location and the number of antibiotics (0 to 8) to which a pathogen
is known to be resistant as predictors. The interaction between predictors was also included in the model
to determine whether environmental isolates respond differently to the resistance of pathogens (62).
Antibiotic susceptibility test. The Kirby-Bauer disk diffusion susceptibility assay was used to test for
antibiotic resistance (63). P. aeruginosa pathogens were spread plated onto Mueller-Hinton agar (BD,
Difco) medium from an overnight culture using a sterile cotton swab. The following eight antibiotic disks
(BD BBL) were placed over the spread plated strains: colistin (10 g), carbenicillin (100 g), chloram-
phenicol (30 g), meropenem (10 g), imipenem (10 g), tobramycin (10 g), ciprofloxacin (5 g), and
ceftazidime (30 g). The diameters of the zones of inhibition were measured after 20 h of incubation.
Pathogens were considered resistant if the zones of inhibition were less than 8 mm for colistin, 13 mm
for carbenicillin, 12 mm for chloramphenicol, 13 mm for meropenem, 13 mm for imipenem, 12 mm for
tobramycin, 15 mm for ciprofloxacin, and 14 mm for ceftazidime (BD BBL Sensi-Disc antimicrobial
susceptibility test disks).
Genome sequencing of isolated env-P strains 02C26, 09C129, LG1D9, and LH1G9. Genomic DNA
was extracted using the Wizard Genomic DNA purification kit (Promega). PacBio sequencing was
performed by the University of Delaware DNA Sequencing and Genotyping Center. Genomic DNA was
sheared using g-TUBE to 20-kb fragments (Covaris). The PacBio libraries were prepared using the
standard PacBio protocol for 20-kb libraries (20-kb template preparation using the BluePippin size
selection system). Each sample library was sequenced on PacBio RS II instrument with one single-
molecule real-time (SMRT) cell using P6-C4 chemistry with a 6-h movie. The genome was assembled
using PacBio Hierarchical Genome Assembly Process 3. The reads of the inserts were filtered by a quality
score of 0.8 and read length of 1 kb (64). All assemblies folded into one contig.
Transposon mutagenesis. Triparental mating was used to deliver the Tn5 mini-transposon from
pBAM1 in E. coli strain CC118 with helper strain HB101 to Pseudomonas strains 02C26, 09C129, LG1D9,
and LH1G9 (60). E. coli and Pseudomonas strains were cultured overnight, as described above. One
milliliter of cells was washed with 10 mM MgSO4 to remove any traces of antibiotics. One hundred
microliters of each strain (CC118, HB101, and one env-P strain) was mixed together in a 1:1:1 ratio and
centrifuged. The pelleted cells were resuspended in 10 l of 10 mM MgSO4, spotted on NB, and
incubated at 30°C for 24 h. The cells were scraped from the plate and resuspended in 200 l of 10 mM
MgSO4, and 100 l was plated onto solid cetrimide agar with 50 g/ml to select for Pseudomonas
transconjugants. Transconjugants were replica plated onto a sensitive P. aeruginosa pathogen and
screened for mutants exhibiting a loss-of-antagonism phenotype. Mutant screens for 02C26, 09C129,
LG1D9, and LH1G9 were performed on the sensitive pathogens AU10014 (P. aeruginosa), AU17108 (P.
aeruginosa), AU33589 (Burkholderia cenocepacia GIIIb), and AU33586 (Burkholderia cepacia), respectively.
Mutant DNA extraction and ARB PCR. Genomic DNA was extracted from the mutant strains 02C26,
09C129, LG1D9, and LH1G9 using the Wizard Genomic DNA purification kit (Promega). Arbitrary PCR
(ARB-PCR) was used to amplify the genomic DNA flanking the Tn insert (60, 65). Two PCR cycles were
performed. ARB-PCR I was performed using 2 l of genomic DNA and 5 M primer ARB6 (GGCACGCG
TCGACTAGTACNNNNNNNNNNACGCC), in combination with 5 mol/liter primer ME-I-extR (CTCGTTTCA
CGCTGAATATGGCTC) or 5 mol/liter primer ME-O-extF (CGGTTTACAAGCATAACTAGTGCGGC). The con-
ditions for the ARB-PCR I were 5 min at 95°C, six cycles of 30 s at 95°C, 30 s at 30°C, and 90 s at 72°C, 30
cycles of 30 s at 95°C, 30 s at 45°C, and 90 s at 72°C, and an extension period of 4 min at 72°C. For the
second round of ARB-PCR, 1 l of ARB-PCR I product was used as the template. ARB-PCR II was performed
using 1 l of ARB-PCR I product and 5 mol/liter primer ARB2 (GGCACGCGTCGACTAGTAC) in combina-
tion with 5 mol/liter primer ME-I-intR (CAGTTTTATTGTTCATGATGATATA) or 5 mol/liter primer ME-O-
intF (AGAGGATCCCCGGGTACCGAGCTCG). The conditions for ARB-PCR II were 60 s at 95°C, 30 cycles of
30 s at 95°C, 30 s at 52°C, and 90 s at 72°C, followed by an extension period of 4 min at 72°C. PCR
purification was performed on each ARB-PCR II product using the NucleoSpin gel and PCR cleanup kit
(Macherey-Nagel). Samples were sequenced at the University of Chicago Comprehensive Cancer Center
DNA Sequencing and Genotyping Facility using either ME-I intR primer or ME-O intF primer.
Genome annotation and BGC characterization. Genomes were annotated using the JGI Genomes
On Line Database (GOLD [24, 66]). BGCs were initially identifed by utilizing both the JGI Integrated Microbial
Genomes (IMG) system (67, 68) and antibiotics & Secondary Metabolite Analysis Shell (antiSMASH [42, 69]).
JGI IMG provides the number of BGCs present in a genome under the Genome Statistics section, and
antiSMASH is a program dedicated to the identification of gene clusters that encode secondary
metabolites. BGCs were further characterized through the JGI IMG Atlas of Biosynthetic gene Clusters
(ABC [32]). A heat map was constructed using the JGI ABC portal to visualize BGC diversity. BGCs were
searched in the database for protein families (Pfam) that had similar content based on the number and
type of protein families. The top 95 hits were used to generate the heat map. The Jaccard index and
modified Jaccard index scores were applied to determine similar clusters.
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Data availability. All gyrB gene sequences are available through GenBank accession numbers
MH671920 to MH672390. The genomes of strains 02C26 (LE5C2), 09C129 (LE6C9), LG1D9, and LH1G9 are
available through GenBank accession numbers CP025262, CP025261, CP026881, and CP026880 and JGI
IMG genome ID numbers 2706794715, 2703719185, 2716884900, and 2740891816, respectively.
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